FrancophonIA/ELRC3.0 huggingface dataset:
English: Common Diarrhoea, Nausea Abdominal pain, Constipation, Dry mouth, Flatulence, Stomach discomfort, Vomiting
Estonian: Kõhuvalu, kõhukinnisus, suukuivus, kõhupuhitus, ebamugavustunne maos, oksendamine
English: Uncommon Dysgeusia, Hypersomnia, Muscle spasticity, Syncope, Fall
Estonian: Maitsetundlikkuse häired, hüpersomnia, lihaste spastilisus, minestamine, kukkumine
English: Gastric lavage may be of use.
Estonian: Teha võib maoloputust.
English: Cardiac effects
Estonian: Südame häired
English: NUEDEXTA 15 mg/9 mg hard capsules
Estonian: NUEDEXTA 15 mg / 9 mg kõvakapslid
English: NUEDEXTA 23 mg/9 mg hard capsules
Estonian: NUEDEXTA 23 mg / 9 mg kõvakapslid
English: Chest discomfort, Chest pain, Chills, Feeling hot, Gait disturbance, Influenza like illness, Pyrexia, Oxygen
Estonian: Ebamugavustunne rinnus, valu rinnus, külmavärinad, kuumatunne, koordinatsioonihäired, gripilaadne haigus, püreksia, vähenenud hapnikusaturatsioon
English: Each capsule contains dextromethorphan hydrobromide monohydrate, equivalent to 23.11 mg dextromethorphan and quinidine sulfate dihydrate, equivalent to 8.69 mg quinidine.
Estonian: Üks kapsel sisaldab dekstrometorfaanvesinikbromiidmonohüdraati, mis vastab 23,11 mg dekstrometorfaanile, ja kinidiinsulfaatdihüdraati, mis vastab 8,69 mg kinidiinile.
English: BOTTLE LABEL (60 hard capsules) - NUEDEXTA 23 mg/9 mg capsules
Estonian: PUDELI ETIKETT (60 kõvakapslit) - NUEDEXTA 23 mg / 9 mg kapslid
English: PBA is a consequence of neurological diseases affecting the brain, or brain, injury and is defined by episodes of involuntary, uncontrollable emotional expressions of laughing and/or crying that are incongruous or disproportionate to the patient's emotional state or mood.
Estonian: Seda iseloomustavad tahtmatud, kontrollimatu naeru ja/või nutuga kulgevad emotsionaalsed tundepursked, mis ei ole kooskõlas ega vastavuses patsiendi emotsionaalse seisundi või meeleoluga.
English: MAOIs
Estonian: Sugu
English: BOTTLE CARTON (60 hard capsules) - NUEDEXTA 23 mg/9 mg capsules
Estonian: PUDELI PAPPKARP (60 kõvakapslit) - NUEDEXTA 23 mg / 9 mg kapslid
English: Each capsule contains dextromethorphan hydrobromide monohydrate, equivalent to 15.41 mg dextromethorphan and quinidine sulfate dihydrate, equivalent to 8.69 mg quinidine.
Estonian: Üks kapsel sisaldab dekstrometorfaanvesinikbromiidmonohüdraati, mis vastab 15,41 mg dekstrometorfaanile, ja kinidiinsulfaatdihüdraati, mis vastab 8,69 mg kinidiinile.
English: BOTTLE LABEL (60 hard capsules) - NUEDEXTA 15 mg/9 mg capsules
Estonian: PUDELI ETIKETT (60 kõvakapslit) - NUEDEXTA 15 mg / 9 mg kapslid
English: Frequency Adverse Reaction
Estonian: Seedetrakti häired
English: Drug interactions with desipramine and paroxetine have been studied in controlled clinical trials with a higher dose combination of dextromethorphan/quinidine (dextromethorphan 23 mg/ quinidine 26 mg) than in this medicinal product; study results are described below.
Estonian: Kontrollitud kliinilistes uuringutes on uuritud koostoimet desipramiini ja paroksetiiniga, kasutades suuremaid dekstrometorfaani/kinidiini annuseid (dekstrometorfaan 23 mg / kinidiin 26 mg), kui NUEDEXTA sisaldab.
English: • fatigue
Estonian: Rasedus
English: Liver enzyme inducers
Estonian: Monoamiinoksüdaasi inhibiitorid
English: BOTTLE CARTON (60 hard capsules) - NUEDEXTA 15 mg/9 mg capsules
Estonian: PUDELI PAPPKARP (60 kõvakapslit) - NUEDEXTA 15 mg / 9 mg kapslid
English: Quinidine at higher doses has also been associated with a lupus-like syndrome involving polyarthritis, sometimes with a positive antinuclear antibody test. Other associations include rash, bronchospasm, lymphadenopathy, haemolytic anaemia, vasculitis, uveitis, angioedema, agranulocytosis, the sicca syndrome, myalgia, elevation in serum levels of skeletal-muscle enzymes, and pneumonitis.
Estonian: Muude nähtude hulka kuuluvad lööve, bronhospasm, lümfadenopaatia, hemolüütiline aneemia, vaskuliit, uveiit, angioödeem, agranulotsütoos, kuiv sündroom, lihasvalu, skeletilihasensüümide sisalduse suurenemine seerumis ja pneumoniit.
English: Regardless of which strength of NUEDEXTA has been prescribed to you: • continue the treatment with: two capsules per day (one capsule every 12 hours).
Estonian: Olenemata teile välja kirjutatud NUEDEXTA tugevusest: • jätkake ravi:
English: Musculoskeletal stiffness, Myalgia, Neck pain, Pain in
Estonian: Harv Skeletilihaste jäikus, lihasvalu, kaelavalu, jäsemevalu
English: • Epistaxis, Pharyngolaryngeal pain, Respiratory depression, Rhinorrhoea, Yawning
Estonian: Ninaverejooks, farüngolarüngaalne valu, hingamise aeglustumine, rinorröa, haigutamine
English: Non-specific symptoms, such as light-headedness, chills, fever, nausea, and vomiting, can precede or occur with thrombocytopenia.
Estonian: Trombotsütopeeniale võivad eelneda või sellega kaasneda mittespetsiifilised haigusnähud, nagu minestamistunne, külmavärinad, palavik, iiveldus ja oksendamine.
English: • rash
Estonian: • lööve;
English: • chest discomfort, chest pain, chills, feeling hot, gait disturbance (difficulty walking), flu-like illness, fever, decreased oxygen levels in the blood
Estonian: (kõndimishäired), gripilaadne haigus, palavik, vere hapnikusisalduse vähenemine;
English: In a drug-drug interaction study, a higher combination dose of dextromethorphan/quinidine (dextromethorphan 23 mg/quinidine 26 mg) was added to paroxetine at steady state.
Estonian: Ravimite koostoimeuuringus lisati dekstrometorfaani/kinidiini kombineeritud annus (dekstrometorfaan 23 mg / kinidiin 26 mg) paroksetiinile (tasakaalukontsentratsioonid).
English: Common Dizziness, Headache, Somnolence
Estonian: • pearinglus, peavalu, unisus;
English: • diarrhoea, nausea
Estonian: • kõhulahtisus, iiveldus;
English: Non-clinical data reveal no special hazard for a genotoxicity or carcinogenic potential, nor for fertility impairment.
Estonian: Genotoksilisuse, kartsinogeensuse ja viljakushäirete uuringud ei ole näidanud kahjulikku toimet inimesele.
English: Neither dextromethorphan alone nor dextromethorphan/quinidine has been evaluated in patients with severe hepatic impairment.
Estonian: Raske maksakahjustusega patsientidel ei ole dekstrometorfaani monoteraapiat ega dekstrometorfaani/kinidiini toimet uuritud.
English: Gastrointestinal disorders
Estonian: Trombotsütopeenia
English: insomnia, restlessness, disturbed sleep
Estonian: Harv Kahelinägemine, ähmane nägemine
English: Two of the studies lasted 6 months, and two lasted 1 year.
Estonian: Kaks uuringut kestsid 6 kuud ja kaks 1 aasta.
English: Its effect may improve further for up to 6 months.
Estonian: Toime võib tugevneda kuni 6 kuu vältel.
English: The two longer studies were then extended, with patients remaining on the medicines for at least 1 more year.
Estonian: Kaht pikemat uuringut pikendati, kasutades patsientidel samu ravimeid veel vähemalt 1 aasta jooksul.
English: These results were maintained in the extension studies.
Estonian: Tulemused püsisid ka jätku-uuringutes.
English: The medicine usually starts to have an effect after 4 to 6 weeks.
Estonian: Ravimi toime ilmneb tavaliselt 4-6 nädala pärast.
English: Further information on Leflunomide Zentiva can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/leflunomide-zentiva.
Estonian: Lisateave Leflunomide Zentiva kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/leflunomide-zentiva.
English: Leflunomide Zentiva received a marketing authorisation valid throughout the EU on 8 January 2010.
Estonian: Leflunomide Zentiva on saanud müügiloa, mis kehtib kogu ELis, 8. jaanuaril 2010.
English: This authorisation was based on the authorisation granted to Arava in 1999 (‘informed consent').
Estonian: Müügiluba põhineb 1999. aastal antud Arava müügiloal (teabel põhinev nõusolek).
English: Leflunomide Zentiva1 (leflunomide)
Estonian: Leflunomide Zentiva1 (leflunomiid)
English: • serious infections;
Estonian: • raske infektsioon;
English: Leflunomide Zentiva is available as tablets (10 mg, 20 mg and 100 mg).
Estonian: Leflunomide Zentivat turustatakse tablettidena (10 mg, 20 mg ja 100 mg).
English: 1 Previously known as Leflunomide Winthrop.
Estonian: 1 Varasem nimetus Leflunomide Winthrop.
English: • severe immunodeficiency states, such as acquired immune deficiency syndrome (AIDS);
Estonian: • raske immuunpuudulikkus, nt omandatud immuunpuudulikkuse sündroom (AIDS);
English: What measures are being taken to ensure the safe and effective use of Leflunomide Zentiva?
Estonian: Mis meetmed võetakse, et tagada Leflunomide Zentiva ohutu ja efektiivne kasutamine?
English: Leflunomide Zentiva must not be used in patients with:
Estonian: Leflunomide Zentivat ei tohi kasutada patsiendid, kellel on:
English: The European Medicines Agency decided that Leflunomide Zentiva's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Leflunomide Zentiva kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: The most common side effects with Leflunomide Zentiva (which may affect up to 1 in 10 people) are leucopenia (low white blood cell counts), mild allergic reactions, increased creatine phosphokinase levels (a marker of muscle damage), paraesthesia (abnormal sensations like pins and needles), peripheral neuropathy (nerve damage in hands and feet), headache, dizziness, mild increases in blood pressure, colitis (inflammation in the large bowel), diarrhoea, nausea (feeling sick), vomiting, inflammation of the mouth such as mouth ulcers, abdominal (belly) pain, increased liver enzyme levels, hair loss, eczema, rash, pruritus (itching), dry skin, tenosynovitis (inflammation of the sheath surrounding the tendons), loss of appetite, weight loss and asthenia (weakness).
Estonian: Leflunomide Zentiva kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on leukopeenia (leukotsüütide (valgeliblede) vähesus), kerged allergiareaktsioonid, kreatiinfosfokinaasi (lihasekahjustuste marker) suurenenud sisaldus, paresteesia (naha vääraistingud, nt kirvendus- või torkimistunne), perifeerne neuropaatia (jalgade ja käte närvikahjustus), peavalu, peapööritus, kerge vererõhu tõus, koliit (jämesoolepõletik), kõhulahtisus, iiveldus, oksendamine, suupõletik, nt suuhaavandid, kõhuvalu, maksaensüümide sisalduse suurenemine, juuste väljalangemine, ekseem, lööve, kihelus, nahakuivus, tenosünoviit (kõõlusetupepõletik), isutus, kaalulangus ja asteenia (nõrkus).
English: What is Leflunomide Zentiva and what is it used for?
Estonian: Mis on Leflunomide Zentiva ja milleks seda kasutatakse?
English: Other information about Leflunomide Zentiva
Estonian: Muu teave Leflunomide Zentiva kohta
English: As for all medicines, data on the use of Leflunomide Zentiva are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Leflunomide Zentiva kasutamise kohta pidevat järelevalvet.
English: Leflunomide Zentiva must not be used in pregnant women, in women who can become pregnant and who are not using reliable contraception or during breast-feeding.
Estonian: Leflunomide Zentivat ei tohi kasutada rasedad, rasestuda võivad patsiendid ega patsiendid, kes ei kasuta efektiivseid rasestumisvastaseid vahendeid, samuti ei tohi seda kasutada imetamise ajal.
English: Leflunomide Zentiva treatment usually starts with a ‘loading dose' of 100 mg once a day for 3 days, followed by a maintenance dose.
Estonian: Ravi Leflunomide Zentivaga alustatakse tavaliselt küllastusannusega 100 mg üks kord ööpäevas 3 päeva jooksul ning seejärel kasutatakse säilitusannust.
English: The recommended maintenance dose is 10 to 20 mg once a day in patients with rheumatoid arthritis, and 20 mg once a day in patients with psoriatic arthritis.
Estonian: Soovitatav säilitusannus on reumatoidartriidiga patsientidel 10-20 mg üks kord ööpäevas ja psoriaatilise artriidiga patsientidel 20 mg üks kord ööpäevas.
English: For more information about using Leflunomide Zentiva, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Leflunomide Zentiva kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: In psoriatic arthritis, a study in 186 patients showed that Leflunomide Zentiva was more effective than placebo over 6 months: 59% of the patients taking Leflunomide Zentiva responded to treatment, compared with 30% of those taking placebo.
Estonian: Psoriaatilise artriidi uuring, milles osales 186 patsienti, tõendas, et 6 kuu järel oli Leflunomide Zentiva efektiivsem kui platseebo: Leflunomide Zentivat kasutanud patsientidest oli ravivastusega patsiente 59% ning platseebot saanutest 30%.
English: • severe hypoproteinaemia (low blood protein levels).
Estonian: • raske hüpoproteineemia (vere väike valgusisaldus).
English: The medicine contains the active substance leflunomide.
Estonian: Ravim sisaldab toimeainena leflunomiidi.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Leflunomide Zentiva have been included in the summary of product characteristics and the package leaflet.
Estonian: Leflunomide Zentiva ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Side effects reported with Leflunomide Zentiva are carefully evaluated and any necessary action taken to protect patients.
Estonian: Leflunomide Zentiva kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Over the first year of treatment, Leflunomide Zentiva was as effective as methotrexate, but only when it was taken with folate (a type of vitamin B).
Estonian: Ravi esimesel aastal oli Leflunomide Zentiva sama efektiivne kui metotreksaat, kuid ainult kasutamisel koos folaadiga (Bvitamiini liik).
English: Leflunomide does this by blocking an enzyme called ‘dihydroorotate dehydrogenase', which is necessary for the lymphocytes to multiply.
Estonian: Leflunomiid toimib, blokeerides ensüümi dihüdroorotaat-dehüdrogenaasi, mida lümfotsüüdid vajavad paljunemiseks.
English: The company that markets Leflunomide Zentiva will ensure that doctors who are expected to prescribe the medicine receive an information pack containing important information on the risks with Leflunomide Zentiva and the monitoring that should be carried out in patients.
Estonian: Leflunomide Zentiva turustaja tagab kõigile ravimit määravatele arstidele teabepakme olulise teabega Leflunomide Zentiva kasutamisega kaasnevate riskide ja patsientide jälgimise kohta.
English: With fewer lymphocytes, there is less inflammation, helping to control the symptoms of arthritis.
Estonian: Kui lümfotsüütide arv väheneb, leeveneb põletik ja artriidi sümptomid vähenevad.
English: They also need to take special care when switching a patient to Leflunomide Zentiva, or when switching a patient who is receiving Leflunomide Zentiva to another treatment.
Estonian: Arst peab olema eriti ettevaatlik ka patsiendi üleviimisel ravile Leflunomide Zentivaga või Leflunomide Zentivat kasutava patsiendi üleviimisel muule ravile.
English: Leflunomide Zentiva was not as effective as methotrexate in the extension study.
Estonian: Leflunomide Zentiva ei olnud jätku-uuringus sama efektiivne kui metotreksaat.
English: In rheumatoid arthritis, Leflunomide Zentiva has been studied in 4 main studies involving over 2,000 patients, in which it was compared with placebo (a dummy treatment), or with methotrexate or sulphasalazine (other medicines used to treat rheumatoid arthritis).
Estonian: Leflunomide Zentivat uuriti 4 reumatoidartriidi põhiuuringus, milles osales üle 2000 patsiendi ning milles võrreldi ravimit platseeboga (näiv ravim) või metotreksaadi või sulfasalasiiniga (samuti reumatoidartriidi ravimid).
English: Leflunomide Zentiva is a medicine used to treat adults with active rheumatoid arthritis (an immune system disease causing inflammation of the joints) or active psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints).
Estonian: Leflunomide Zentivat kasutatakse aktiivse reumatoidartriidi (liigesepõletikku põhjustav immuunsüsteemi haigus) või aktiivse psoriaatilise artriidi (punetavaid ketendavaid laike nahal ja liigesepõletikku põhjustav haigus) raviks täiskasvanutel.
English: Between 49 and 55% of the patients taking Leflunomide Zentiva responded to treatment, compared with 26 to 28% of those taking placebo, and 54% of those taking sulphasalazine.
Estonian: Ravivastusega patsiente oli Leflunomide Zentiva rühmas 49-55%, platseeborühmas 2628% ja sulfasalasiini rühmas 54%.
English: • moderate to severely impaired kidney function;
Estonian: • mõõdukas kuni raske neerupuudulikkus;
English: For the full list of side effects with Leflunomide Zentiva, see the package leaflet.
Estonian: Leflunomide Zentiva kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What are the risks associated with Leflunomide Zentiva?
Estonian: Mis riskid Leflunomide Zentivaga kaasnevad?
English: Doctors prescribing Leflunomide Zentiva need to be aware of the risk of liver problems associated with the medicine.
Estonian: Arst peab Leflunomide Zentiva määramisel arvestama ravimiga kaasnevate maksaprobleemide riski.
English: How is Leflunomide Zentiva used?
Estonian: Kuidas Leflunomide Zentivat kasutatakse?
English: • poor bone marrow function or low blood cell counts (red cells, white cells or platelets) caused by conditions other than rheumatoid or psoriatic arthritis;
Estonian: • luuüdi talitluse häired või vererakkude (erütrotsüütide (punaliblede), leukotsüütide (valgeliblede) või trombotsüütide (vereliistakute)) vähesus muude seisundite tõttu kui reumatoidartriit või psoriaatiline artriit;
English: Results showed that Leflunomide Zentiva was more effective than placebo and as effective as sulphasalazine.
Estonian: Reumatoidartriidi ravis oli Leflunomide Zentiva platseebost efektiivsem ja sama efektiivne kui sulfasalasiin.
English: The active substance in Leflunomide Zentiva, leflunomide, is an immunosuppressant.
Estonian: Leflunomide Zentivas toimeainena sisalduv leflunomiid on immunosupressant (immuunvastust pärssiv aine).
English: An overview of Leflunomide Zentiva and why it is authorised in the EU
Estonian: Ülevaade ravimist Leflunomide Zentiva ja ELis müügiloa väljastamise põhjendus
English: What benefits of Leflunomide Zentiva have been shown in the studies?
Estonian: Milles seisneb uuringute põhjal Leflunomide Zentiva kasulikkus?
English: The doctor should carry out blood tests to check the patient's liver, white blood cell counts and platelet counts before prescribing Leflunomide Zentiva, and regularly during treatment.
Estonian: Arst teeb enne Leflunomide Zentiva määramist ja ravi ajal regulaarselt vereanalüüse patsiendi maksatalitluse ning leukotsüütide (valgeliblede) ja trombotsüütide (vereliistakute) sisalduse kontrollimiseks.
English: It can only be obtained with a prescription and treatment should be started and supervised by a specialist who has experience in the treatment of rheumatoid arthritis and psoriatic arthritis.
Estonian: Ravi tohib alustada reumatoidartriidi ja psoriaatilise artriidi ravis kogenud arst ja see peab toimuma tema järelevalve all.
English: It reduces inflammation by reducing the production of immune cells called ‘lymphocytes', which are responsible for inflammation.
Estonian: Toimeaine leevendab põletikku, vähendades põletikku põhjustavate immuunrakkudelümfotsüütide - teket.
English: • liver disease;
Estonian: • maksahaigus;
English: How does Leflunomide Zentiva work?
Estonian: Kuidas Leflunomide Zentiva toimib?
English: The tablets are swallowed whole with water.
Estonian: Tabletid neelatakse tervelt koos veega.
English: It is available as tablets (0.5 and 1 mg).
Estonian: Seda turustatakse tablettidena (0,5 ja 1 mg).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Champix on 26 September 2006.
Estonian: Euroopa Komisjon andis Champixi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 26. septembril 2006.
English: Champix varenicline
Estonian: Champix varenikliin
English: A risk management plan has been developed to ensure that Champix is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Champixi võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Champix?
Estonian: Mis meetmeid võetakse, et tagada Champixi ohutu ja efektiivne kasutamine?
English: The full EPAR for Champix can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Champixi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Treatment with Champix is more likely to succeed in smokers who are motivated to stop smoking and who are also receiving additional advice and support.
Estonian: Ravi Champixiga õnnestub tõenäolisemalt suitsetajatel, kes on motiveeritud suitsetamisest loobuma ning kes saavad täiendavat nõu ja toetust.
English: In the first week the patient takes one 0.5 mg tablet once a day for three days, followed by one 0.5 mg tablet twice a day for four days.
Estonian: Esimesel nädalal võtab patsient ühe 0,5 mg tableti üks kord ööpäevas kolm päeva järjest, millele järgneb üks 0,5 mg tablett kaks korda ööpäevas neli päeva järjest.
English: Treatment with Champix lasts for 12 weeks.
Estonian: Ravi Champixiga kestab 12 nädalat.
English: The main measure of effectiveness was the number of patients who had completely stopped smoking for four weeks (between week 9 and week 12 of the study), confirmed by laboratory testing of the patients' breath for signs of smoking.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arv, kes olid neljaks nädalaks (uuringu 9.-12. nädalani) täielikult suitsetamisest loobunud, mis tõestati suitsetamismärkide laboratoorse kontrollimisega patsientide hingeõhus.
English: Other information about Champix
Estonian: Muu teave Champixi kohta
English: For the remaining 11 weeks of treatment, the patient takes one 1 mg tablet twice a day.
Estonian: Ülejäänud 11 ravinädala jooksul võtab patsient ühe 1 mg tableti kaks korda ööpäevas.
English: Reduced doses may be used in patients who do not tolerate the medicine or who have kidney problems.
Estonian: Patsientidel, kes ravimit ei talu või kellel on neeruprobleemid, kasutatakse vähendatud annuseid.
English: Champix is a medicine that contains the active substance varenicline.
Estonian: Champix on ravim, mis sisaldab toimeainena varenikliini.
English: The most common side-effects with Champix (seen in more than 1 patient in 10) are nausea (feeling sick), insomnia (difficulty sleeping), abnormal dreams, headache and nasopharyngitis (inflammation of the nose and throat).
Estonian: Champixi kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on iiveldus, unetus, ebanormaalsed unenäod, peavalu ja nasofarüngiit (nina- ja kõripõletik).
English: This is a summary of the European public assessment report (EPAR) for Champix.
Estonian: See on ravimi Champix Euroopa avaliku hindamisaruande kokkuvõte.
English: Champix is used in adults to help them stop smoking.
Estonian: Champixit kasutatakse täiskasvanutel abistava vahendina suitsetamisest loobumisel.
English: The CHMP concluded that the benefits of Champix outweigh its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee järeldas, et Champixi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
English: The patients' target date for quitting was set at one week after starting treatment and the patients were followed up for a further 40 weeks after their treatment to see if they started smoking again.
Estonian: Patsientide suitsetamisest loobumise kuupäevaks määrati nädal pärast ravi alustamist ja patsiente jälgiti veel 40 nädalat pärast ravi, et näha, kas nad alustavad suitsetamist uuesti.